Anrotinib generally refers to Anrotinib Hydrochloride Capsules, which is not effective in the treatment of medullary thyroid carcinoma, and the drug can be used to treat diseases such as non-small cell lung cancer, gene mutation, or interstitial lymphoma kinase positivity. Anrotinib hydrochloride capsule is not effective in the treatment of medullary thyroid carcinoma, which can be used for the treatment of metastatic or locally advanced non-small cell lung cancer that has recurred or progressed after 2 systemic chemotherapy treatments. In addition, this drug can also be used as prescribed by the physician if the patient develops recurrence or progression after treatment with a targeted drug or after treatment with 2 systemic chemotherapies, and there is a gene mutation in the epidermal growth factor receptor or a positive kinase for interstitial lymphoma kinase. In addition, this drug can also be used for the treatment of clear cell sarcoma, vesicular soft tissue sarcoma and other diseases that are in the progressive stage or recurrence after receiving chemotherapy treatment. Note that this drug is contraindicated in patients with hepatic or renal insufficiency, and patients may experience adverse reactions such as hypertension, fatigue, and diarrhea. Patients with medullary thyroid carcinoma need to seek medical treatment promptly and follow the doctor’s instructions. In addition, patients need to apply the drug under the guidance of doctor and cannot use the drug without authorization.